Press Releases

Distributed: Dec 23, 2010

Alerts Login

Share on StockTwits  
Melbourne, Dec 23, 2010 (ABN Newswire) - Benitec Limited (ASX:BLT) (PINK:BNIKF) is pleased to advise that it will receive a dividend of US$161,674 from its licensee, the California-based biotechnology company, Tacere Therapeutics, Inc. ("Tacere").

The dividend relates to Benitec's equity stake in Tacere and the dividend amount represents US$7.06 per outstanding share of Tacere Common Stock.

As previously announced, Benitec has licensed its gene silencing technology (DNA-directed RNAi) for treating Hepatitis C to Tacere and as consideration, Tacere agreed to upfront and milestone payments and future royalties. The equity stake owned by Benitec in Tacere is part of the overall consideration for the licence agreement between the parties.

Tacere are currently working with Pfizer (NYSE:PFE) to further develop and commercialise Tacere's Hepatitis C Virus compounds.

Dr Peter French, Benitec CEO, said that he was very pleased with the dividend payment, as "...it indicates the potential for significant income as Benitec's technology moves through the commercialization process. Clearly the potential is for this and other projects to yield significant value for shareholders in the future."


Share on StockTwits  

Contact

Peter French
Chief Executive Officer
Benitec Limited
Tel: +61-412-457-595
http://www.benitec.com


  Related Companies

>>>        Benitec Biopharma Limited
>>>           Pfizer Inc.

  Related Industry Topics:

Biotech | Drugs & OTC | Financial General | Health & Pharm General | 

  This Page Viewed:  (Last 7 Days: 7) (Last 30 Days: 60) (Since Published: 3217) 

   

  ABN Newswire on Social Media


Site Search

 
 ENGLISH   All Languages
Send A Press Release
Webcast Your Annual General Meeting

Mobile Video TV

qrcode
Scan with your Mobile Phone to view ABN Newswire Video Channel on Mobile